After the July 4 holiday, the U.S. Food and Drug Administration has several items on the regulatory agency’s immediate calendar, including a couple target action dates and an advisory committee hearing.

Infectious disease experts are weighing the need for booster shots of the Pfizer/BioNTech or Moderna mRNA-based vaccines for Americans who received Johnson & Johnson’s one-dose vaccine due to the increasing prevalence of the more contagious Delta coronavirus variant.

Lifebit Biotech Ltd. announced the beginning of a long-term partnership with Boehringer Ingelheim to utilize Natural Language Processing (NLP) and Artificial Intelligence (AI) for the detection and early reporting of global disease outbreaks using real-world data harvested from scientific publications and other open sources.

Thermo Fisher Scientific is acquiring Mesa Biotech for about $450 million in cash, and will pay an additional $100 million in cash after certain milestones are hit.

Affinivax Inc., a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS (Multiple Antigen Presenting System) platform, announced the closing of a $226 million Series C financing.

The world is caught in a perfect storm of rising rates of chronic disease, persistent infectious diseases and public health failures that have fuelled deaths in the Covid-19 pandemic, according to a major global study of human health.

Hexagon Bio, a California-based biotechnology company turning nature’s DNA into medicines for cancers and infectious diseases with unmet needs, will move into clinical research with $47 million in Series A financing.  

Point-of-care testing is a critical tool in the battle against Covid-19, and researchers in Indiana are working around the clock to deliver rapid tests with high specificity.

This panel discussion will feature the top minds in infectious diseases, virology and vaccinology, who will give participants a breakdown of the top vaccine candidates and the latest information on clinical trials.

GlaxoSmithKline and Germany-based CureVac forged a strategic collaboration worth nearly $1 billion to develop up to five messenger RNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens.